261 related articles for article (PubMed ID: 12687332)
1. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
Niemi M; Backman JT; Neuvonen M; Neuvonen PJ
Diabetologia; 2003 Mar; 46(3):347-51. PubMed ID: 12687332
[TBL] [Abstract][Full Text] [Related]
2. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
[TBL] [Abstract][Full Text] [Related]
3. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
Niemi M; Backman JT; Juntti-Patinen L; Neuvonen M; Neuvonen PJ
Br J Clin Pharmacol; 2005 Aug; 60(2):208-17. PubMed ID: 16042675
[TBL] [Abstract][Full Text] [Related]
4. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
Kajosaari LI; Niemi M; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2006 Mar; 79(3):231-42. PubMed ID: 16513447
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
Kudo T; Hisaka A; Sugiyama Y; Ito K
Drug Metab Dispos; 2013 Feb; 41(2):362-71. PubMed ID: 23139378
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
7. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.
Tornio A; Niemi M; Neuvonen M; Laitila J; Kalliokoski A; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2008 Sep; 84(3):403-11. PubMed ID: 18388877
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses.
Honkalammi J; Niemi M; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2011 Oct; 39(10):1977-86. PubMed ID: 21778352
[TBL] [Abstract][Full Text] [Related]
10. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide.
Niemi M; Tornio A; Pasanen MK; Fredrikson H; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2006 Jun; 62(6):463-72. PubMed ID: 16758263
[TBL] [Abstract][Full Text] [Related]
11. Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans.
Honkalammi J; Niemi M; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2011 Apr; 89(4):579-86. PubMed ID: 21368757
[TBL] [Abstract][Full Text] [Related]
12. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects.
Niemi M; Kajosaari LI; Neuvonen M; Backman JT; Neuvonen PJ
Br J Clin Pharmacol; 2004 Apr; 57(4):441-7. PubMed ID: 15025742
[TBL] [Abstract][Full Text] [Related]
13. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
Kalliokoski A; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2008 Oct; 84(4):488-96. PubMed ID: 19238654
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
Kajosaari LI; Jaakkola T; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2006 Mar; 62(3):217-23. PubMed ID: 16447051
[TBL] [Abstract][Full Text] [Related]
15. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.
Niemi M; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Jul; 70(1):58-65. PubMed ID: 11452245
[TBL] [Abstract][Full Text] [Related]
16. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.
Tomalik-Scharte D; Fuhr U; Hellmich M; Frank D; Doroshyenko O; Jetter A; Stingl JC
Drug Metab Dispos; 2011 May; 39(5):927-32. PubMed ID: 21270106
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
Niemi M; Leathart JB; Neuvonen M; Backman JT; Daly AK; Neuvonen PJ
Clin Pharmacol Ther; 2003 Oct; 74(4):380-7. PubMed ID: 14534525
[TBL] [Abstract][Full Text] [Related]
18. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
19. Rifampin decreases the plasma concentrations and effects of repaglinide.
Niemi M; Backman JT; Neuvonen M; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2000 Nov; 68(5):495-500. PubMed ID: 11103752
[TBL] [Abstract][Full Text] [Related]
20. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Scheen AJ
Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
